Abiopharma

🔍 Slaughter Richard Colby (Executive)

Company: STANDEX INTERNATIONAL CORP/DE/ (SXI)

Report Date: 2026-08-23

Detailed Transactions and Holdings:

• Acquired 1,049 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-23 | Code: A | equity_swap_involved: 0 | shares_owned_after: 1,049.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F1
• Acquired 1,049 shares of Phantom Stock Units (Derivative)
  Date: 2026-08-23 | Code: A | Expires: 2029-08-23 | Exercise: 2029-08-23 | equity_swap_involved: 0 | shares_owned_after: 1,049.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2
• Acquired 5,734 shares of Stock Option (Derivative)
  Date: 2026-08-23 | Code: A | equity_swap_involved: 0 | shares_owned_after: 5,734.00 | transaction_form_type: 4 | Footnotes: F3, F3, F3, F3, F3

Footnotes:

• F1: Grant of Restricted Stock Units pursuant to the 2018 Omnibus Incentive Plan of the Company which vests one-third per year on each anniversary of the date of the award.
• F2: Award of Performance Share Units pursuant to the 2018 Omnibus Incentive Plan of the Company. These shares cliff vest at the end of a three year performance period with the ultimate number of shares ranging from 0 to 250% of the award based on achievement against Company performance metrics of the three year period.
• F3: Premium Priced Stock Option with exercise price 10% above the closing market price on the date of grant. Option vests 25% per year on each anniversary of the date of the award for four years. This option expires ten years from the date of grant.